Acta Scientific Clinical Case Reports

Research ArticleVolume 3 Issue 10

A Pilot Study to Understand an Impact During the COVID-19 Lockdown in Clinical Trial Monitoring Activities and its Management

Heema Desai1 and Kaushal Kapadia2*

1Ph.D. Clinical Research (Student), Texila American University, Mumbai, Maharashtra, India
2Ph.D. Clinical Research, A Clinical Research Professional, Mumbai, Maharashtra, India

*Corresponding Author: Kaushal Kapadia, Ph.D. Clinical Research, A Clinical Research Professional, Mumbai, Maharashtra, India.

Received: August 25, 2022; Published: September 22, 2022

Abstract

COVID-19 pandemic has hit the global healthcare and research surface with a staggering blow, however, with some drawbacks and imperfections the clinical research fraternity worldwide has held up the principles of rights, safety and well-being of patients. Lack of logistical, transport permissions in different parts of the world alongside the severe infection capacity of the deadly virus had put intermittent pauses to clinical trials in the last two years. This survey based observational study focuses on the real-time experience and opinions of the clinical research associates (CRAs) who had been carrying on with their on-going clinical trials unperturbed with the apparent obstacles. The respondents faced different types of issues in the accountability of investigational product, accessibility to central laboratories, conformity review of informed consent of the subjects, and most importantly, complexities in the adapted new methods of source data verifications in their monitoring activities. The suggestions generated in the survey on how the existing loopholes can be addressed and what should be the focus on such changed model of monitoring, were highlighted. In the lines of ongoing initiatives by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), the various clinical trials strategic working groups, and regulatory authorities like USFDA, this survey-based study highlights the need of technology adoption. Going forward, remote and hybrid monitoring models can be cost-effective and possibly more efficient than onsite visit-based monitoring model.

Keywords: COVID-19; Remote Monitoring; Risk Based Monitoring; Hybrid Monitoring

Bibliography

  1. Ledford H. “The COVID pandemic’s lingering impact on clinical trials”. Nature 595 (2021): 341-342.
  2. The International Council for Harmonisation. ICH E6 Guideline for Good Clinical Practice (GCP)– Update on Progress — Public Web Conference Report. May (2021).
  3. van Dorn Aaron. "COVID-19 and readjusting clinical trials”. The Lancet10250 (2020): 523-524.
  4. Turner J Rick. “New FDA guidance on general clinical trial conduct in the era of COVID-19”. Therapeutic Innovation and Regulatory Science4 (2020): 723-724.
  5. European Commission. “Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic (version 5)”. Belgium (2022).
  6. https://health.ec.europa.eu/system/files/2022-02/guidanceclinicaltrials_covid19_en_1.pdf
  7. Padala Prasad R., et al. "Conducting clinical research during the COVID-19 pandemic: investigator and participant perspectives”. JMIR Public Health and Surveillance2 (2020): e18887.
  8. Gobat N., et al. "What the public think about participation in medical research during an influenza pandemic: an international cross-sectional survey”. Public Health177 (2019): 80-94.
  9. Hashem H., et al. “Obstacles and Considerations Related to Clinical Trial Research During the COVID-19 Pandemic”. Frontiers in Medicine 7 (2020): 598038.
  10. Fowler Robert A., et al. "Early observational research and registries during the 2009–2010 influenza A pandemic”. Critical Care Medicine40 (2010): e120.
  11. Rothe C., et al. “Transmission of 2019-nCoV infection from an asymptomatic contact in Germany”. The New England Journal of Medicine 10 (2020): 970-971.
  12. Bauchner Howard., et al. "Editorial concern—possible reporting of the same patients with COVID-19 in different reports”. Jama13 (2020): 1256-1256.
  13. Jackson Debra., et al. "Vulnerability of nurse and physicians with COVID‐19: Monitoring and surveillance needed”. Journal of Clinical Nursing (2020).
  14. Daly John., et al. "Who speaks for nursing? COVID‐19 highlighting gaps in leadership”. Journal of Clinical Nursing (2020).
  15. Maguire Brittany J and Philippe J Guérin. "A living systematic review protocol for COVID-19 clinical trial registrations”. Wellcome Open Research5 (2020).
  16. Cattani M. COVID-19 Clinical Research Coalition. Electronic address: nick. white@ covid19crc. org. “Global coalition to accelerate COVID-19 clinical research in resource-limited settings”. Lancet395 (2020): 1322-1325.
  17. Rice Todd W and David R Janz. "In defense of evidence-based medicine for the treatment of COVID-19 acute respiratory distress syndrome”. Annals of the American Thoracic Society7 (2020): 787-789.
  18. RoemerPhillip E., et al. "Rapid implementation of an outpatient Covid-19 monitoring program”. NEJM Catalyst Innovations in Care Delivery (2020).
  19. Thornton Jacqui. "The “virtual wards” supporting patients with covid-19 in the community”. BMJ: British Medical Journal (Online)369 (2020).
  20. Ko Stephanie Q., et al. "Remote monitoring of marginalised populations affected by COVID-19: a retrospective review”. BMJ Open12 (2020): e042647.

Citation: Heema Desai and Kaushal Kapadia. “A Pilot Study to Understand an Impact During the COVID-19 Lockdown in Clinical Trial Monitoring Activities and its Management". Acta Scientific Clinical Case Reports 3.10 (2022): 21-26.

Copyright: © 2022 Heema Desai and Kaushal Kapadia. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



News and Events


Contact US